It can predict the recurrence risk and estimate the benefit of adjuvant chemotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer [8,9,10]. Here, ERBB2 is linked to breast cancer.